Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-14
2010-11-16
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S412000, C548S452000, C548S465000
Reexamination Certificate
active
07834048
ABSTRACT:
The present invention relates to a compound of the formula (I)whereinR1is H, C1-C6-alkyl which may be substituted by C3-C6-cycloalkyl, fluorinated C1-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl;A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF3;E is NR5or CH2, wherein R5is H or C1-C3-alkyl;Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra; wherein the variable Rahas the meanings given in the claims and in the description;and physiologically tolerated acid addition salts thereof.The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
REFERENCES:
patent: 5475105 (1995-12-01), Steiner et al.
patent: 5521209 (1996-05-01), Steiner et al.
patent: 5708018 (1998-01-01), Haadsma-Svensson et al.
patent: 5753690 (1998-05-01), Steiner et al.
patent: 6028073 (2000-02-01), Steiner et al.
patent: 6423717 (2002-07-01), Bromidge et al.
patent: 2004/0152724 (2004-08-01), Dart et al.
patent: WO 95/04713 (1995-02-01), None
patent: WO 96/23760 (1996-08-01), None
patent: WO 97/45403 (1997-12-01), None
patent: WO 97/45503 (1997-12-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 99/58499 (1999-11-01), None
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
J.C. Schwartz et al., The Dopamine D, Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York, 1992, pp. 135-144.
M. Dooley et al., Drugs and Aging 1998, 12, 495-514.
J. N. Joyce, Pharmacology and Therapeutics 2001, 90, pp. 231-259 “The Dopamine D3Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs”.
P. Sokoloff et al., Localization and Function of the D3Dopamine Receptor, Arzneim. Frosch./Drug Res. 42(1), 224 (1992).
P. Sokoloff et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, 347, 146 (1990).
Joyce, J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacology and Therapeutics, 2001; 90:231-59.
Laszy, J., et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology, 2005; 179:567-75.
Heidbreder, C.A., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Reviews, 2005; 49:77-105.
Rogoz, Z., et al. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Polish Journal of Pharmacology, 2003; 55:449-54.
Muhlbauer, B., et al. Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiologica Scandinavica, 2000;168(1):219-23.
Benoit, S.C., et al. Altered feeding responses in mice with targeted disruption of the dopamine-3 receptor gene. Behavioral Neuroscience, 2000; 117(1):46-54.
Braje Wilfried
Drescher Karla
Grandel Roland
Haupt Andreas
Turner Sean C.
Abbott & GmbH & Co. KG
Anderson Rebecca L
Mueller Lisa V.
Nolan Jason M
Polsinelli Shughart PC
LandOfFree
Azabicycloheptyl compounds suitable for treating disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicycloheptyl compounds suitable for treating disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicycloheptyl compounds suitable for treating disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160909